- Home
- PTGX vs TMDX Comparison
PTGX vs TMDX Comparison
Compare PTGX & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | TMDX |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 3.9B |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PTGX | TMDX |
|---|---|---|
| Price | $89.29 | $136.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $86.44 | ★ $133.00 |
| AVG Volume (30 Days) | ★ 898.7K | 835.5K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.70 |
| EPS | 0.72 | ★ 2.54 |
| Revenue | $209,217,000.00 | ★ $566,354,000.00 |
| Revenue This Year | N/A | $38.84 |
| Revenue Next Year | $296.47 | $20.43 |
| P/E Ratio | $124.48 | ★ $53.83 |
| Revenue Growth | N/A | ★ 41.20 |
| 52 Week Low | $33.70 | $55.00 |
| 52 Week High | $93.25 | $156.00 |
Technical Indicators
Market Signals| Indicator | PTGX | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 64.67 | 54.31 |
| Support Level | $83.52 | $133.50 |
| Resistance Level | $90.85 | $156.00 |
| Average True Range (ATR) | 2.63 | 8.50 |
| MACD | -0.33 | 0.41 |
| Stochastic Oscillator | 83.62 | 55.98 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.